· Patients with diabetes treated by diet or tablets no longer need to inform the DVLA unless they develop other complications or have frequent episodes of hypoglycaemia (see patient information sheet in “At a glance guide”). Teneligliptin, a new third generation oral anti-diabetic agent is used for the management of Type-2 Diabetes mellitus. Here, we compared the effects of linagliptin versus sitagliptin and liraglutide on survival and vascular function in animal models of endotoxic shock by prophylactic therapy and treatment after lipopolysaccharide (LPS) injection. As per IDF (International Diabetes Federation) there were more than 7 crores diabetic patients in India for the year 2014 and this figure will rise significantly to 11 crores.Asmost of the patient population resides in rural India or belong to middle class,Mankindhas launched thisaffordable anti-diabetic drug so that substantial financial burden of this segment of population in India is reduced. We will mainly consider the use of gliptins in patients with recently diagnosed T2D, in elderly and frail patients and in those with chronic kidney disease. In type 2 diabetes GLP-1 activity is blunted resulting in hyperglycemia . By increasing the level of incretins — a group of metabolic hormones involved in the lowering of blood glucose — gliptins also hold promise to effectively decrease Parkinson’s symptoms.
Gliptins are agents, which inhibits the enzyme DPP-4 thereby increasing the circulatory time of GLP-1 and hence restoring its actions.